Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How business will affect pharmaceutical reps

Steve Woodruff
Meds
May 11, 2011
Share
Tweet
Share

There’s been a lot of talk in the past year about how we need to re-think the role and profile of the pharmaceutical/biotech sales rep.

This dialogue needs to happen, given the trends that are rapidly shrinking the size of sales forces. Of course, when you poll the doctors, they are going to focus on the need for greater depth of clinical knowledge. That’s certainly important. And, if you talk to the rest of the staff, then knowledge of health plans and administrative/business issues rise to the surface. As you’d expect.

But now, let’s take a look at it from the shoes of the pharmaceutical company – the executives and managers responsible for outreach to the medical community. What does the new new rep need to look like with their perspective in mind?

The old model had much to do with reach and frequency – getting the message out. Looking ahead, I think it’s going to require a mentality much more focused on opportunity and strategy – that is, approaching one’s job as a business, and intelligently using available information to maximize proper patient use of the most appropriate therapy.

Often this includes training in something like business acumen, but perhaps a more helpful description of the overall mindset would be something along the lines of business opportunism – savviness/insight joined to creative initiative and enterprising strategy (including pulling in other resources) to accomplish the desired business end. And while one means may be messaging with reach and frequency in mind, that is certainly NOT the end!

A business opportunist would look at the accounts in a territory with a thoughtful finger on the pulse of prescribing volume AND current prescribing habits AND treatment practices AND health plan coverage variations AND patient flow AND other important variables, and be empowered to ask this question: “Where is the greatest potential impact for the most (appropriate) patients?” This is a very different mindset than, “How can I make my call numbers this week?”

Better clinical training instead of meal-and-message-delivery services? Absolutely. Healthcare and office process knowledge? Certainly. But perhaps it’s time to re-think the whole sales rep model, and start deploying business opportunists. I’m thinking advanced training for reps who have been in the field for a year or two should be geared more toward strategic business skills.

Steve Woodruff is Founder and President of Impactiviti.

Submit a guest post and be heard on social media’s leading physician voice.

Prev

How podcasts can help patients with health literacy

May 11, 2011 Kevin 2
…
Next

My interviews on patient engagement and social media

May 11, 2011 Kevin 1
…

Tagged as: Medications

Post navigation

< Previous Post
How podcasts can help patients with health literacy
Next Post >
My interviews on patient engagement and social media

ADVERTISEMENT

More by Steve Woodruff

  • a desk with keyboard and ipad with the kevinmd logo

    Educated online by people with diabetes

    Steve Woodruff
  • a desk with keyboard and ipad with the kevinmd logo

    Why the female Viagra quest is fundamentally misguided

    Steve Woodruff
  • a desk with keyboard and ipad with the kevinmd logo

    How drug information fine print fails to communicate

    Steve Woodruff

More in Meds

  • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

    Adwait Chafale
  • A psychiatrist’s 20-year journey with ketamine

    Muhamad Aly Rifai, MD
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Most Popular

  • Past Week

    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • From nurse practitioner to leader in quality improvement [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
  • Recent Posts

    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • My first week on night float as a medical student

      Amish Jain | Education
    • What Beauty and the Beast taught me about risk

      Jayson Greenberg, MD | Physician
    • Creating safe, authentic group experiences

      Diane W. Shannon, MD, MPH | Physician
    • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

      Adwait Chafale | Meds
    • Healing from medical training by learning to trust your body again [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 10 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • IMGs are the future of U.S. primary care

      Adam Brandon Bondoc, MD | Physician
    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • From nurse practitioner to leader in quality improvement [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • Love, birds, and fries: a story of innocence and connection

      Dr. Damane Zehra | Physician
  • Recent Posts

    • How I learned to love my unique name as a doctor

      Zoran Naumovski, MD | Physician
    • My first week on night float as a medical student

      Amish Jain | Education
    • What Beauty and the Beast taught me about risk

      Jayson Greenberg, MD | Physician
    • Creating safe, authentic group experiences

      Diane W. Shannon, MD, MPH | Physician
    • The diseconomics of scale: How Indian pharma’s race to scale backfires on U.S. patients

      Adwait Chafale | Meds
    • Healing from medical training by learning to trust your body again [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How business will affect pharmaceutical reps
10 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...